Capricor Therapeutics
CAPR
61 hedge funds and large institutions have $30.7M invested in Capricor Therapeutics in 2024 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 17 closing their positions.
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
9% more funds holding
Funds holding: 56 → 61 (+5)
4.75% more ownership
Funds ownership: 15.35% → 20.1% (+4.7%)
6% less capital invested
Capital invested by funds: $32.7M → $30.7M (-$2.06M)
26% less call options, than puts
Call options by funds: $1.36M | Put options by funds: $1.84M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.95M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.75M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.59M |
| 4 |
Millennium Management
New York
|
+$1.04M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.54M |
| 2 |
Goldman Sachs
New York
|
-$728K |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$689K |
| 4 |
HF
HRT Financial
New York
|
-$560K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$542K |
CAPR Hedge Fund Activity: Q2 2024 in Review
61 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q2 2024, worth a combined $30.7M — down 6.3% from $32.7M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CAPR positions and 17 closed out — a net gain of 5 holders — while 18 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $6.95M. The largest seller was Susquehanna International Group, cutting an estimated $1.54M.
- 61 institutional investors held Capricor Therapeutics (CAPR) as of Q2 2024, up from 56 in Q1 2024.
- Funds reported $30.7M of Capricor Therapeutics stock for Q2 2024, down 6.3% quarter-over-quarter.
- 22 funds opened new Capricor Therapeutics positions in Q2 2024 and 17 closed out, a net change of +5 holders.
- The largest Capricor Therapeutics buyer in Q2 2024 was BlackRock, an estimated $6.95M added.
- The largest Capricor Therapeutics seller in Q2 2024 was Susquehanna International Group, an estimated $1.54M sold.
Based on aggregated 13F filings for Q2 2024.